DE69518334T2 - Pharmazeutische aerosol welche mindestens ein zucker enthält - Google Patents

Pharmazeutische aerosol welche mindestens ein zucker enthält

Info

Publication number
DE69518334T2
DE69518334T2 DE69518334T DE69518334T DE69518334T2 DE 69518334 T2 DE69518334 T2 DE 69518334T2 DE 69518334 T DE69518334 T DE 69518334T DE 69518334 T DE69518334 T DE 69518334T DE 69518334 T2 DE69518334 T2 DE 69518334T2
Authority
DE
Germany
Prior art keywords
pct
pharmaceutical aerosol
sugar
inhalation
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69518334T
Other languages
English (en)
Other versions
DE69518334D1 (de
Inventor
Peter Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69518334D1 publication Critical patent/DE69518334D1/de
Application granted granted Critical
Publication of DE69518334T2 publication Critical patent/DE69518334T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
DE69518334T 1994-12-24 1995-12-22 Pharmazeutische aerosol welche mindestens ein zucker enthält Expired - Fee Related DE69518334T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426252.4A GB9426252D0 (en) 1994-12-24 1994-12-24 Pharmaceutical composition
PCT/EP1995/005085 WO1996019968A1 (en) 1994-12-24 1995-12-22 Pharmaceutical aerosol containing at least one sugar

Publications (2)

Publication Number Publication Date
DE69518334D1 DE69518334D1 (de) 2000-09-14
DE69518334T2 true DE69518334T2 (de) 2001-01-25

Family

ID=10766615

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518334T Expired - Fee Related DE69518334T2 (de) 1994-12-24 1995-12-22 Pharmazeutische aerosol welche mindestens ein zucker enthält

Country Status (12)

Country Link
US (1) US5955439A (de)
EP (1) EP0799024B1 (de)
JP (1) JP3776124B2 (de)
AT (1) ATE195249T1 (de)
AU (1) AU4346996A (de)
DE (1) DE69518334T2 (de)
DK (1) DK0799024T3 (de)
ES (1) ES2150022T3 (de)
GB (1) GB9426252D0 (de)
GR (1) GR3034477T3 (de)
PT (1) PT799024E (de)
WO (1) WO1996019968A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
ES2146192T1 (es) * 1997-03-18 2000-08-01 Basf Ag Metodo y composiciones para modular la sensibilidad a los corticosteroides.
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
AR018183A1 (es) * 1998-04-18 2001-10-31 Glaxo Group Ltd Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ATE289825T1 (de) * 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
CA2725731A1 (en) 1999-06-05 2000-12-14 Innovata Biomed Limited Delivery system
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
DE10043509A1 (de) * 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0102902D0 (en) * 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
JP5154732B2 (ja) * 2001-02-06 2013-02-27 イノバータ・バイオメッド・リミテッド 薬剤
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DK1273292T3 (da) 2001-07-02 2004-10-04 Chiesi Farma Spa Optimeret tobramycinformulering til aerosoldannelse
GB0128148D0 (en) * 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
JP2007533387A (ja) 2004-04-21 2007-11-22 イノベータ バイオメド リミテッド 吸入器
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
US9179691B2 (en) 2007-12-14 2015-11-10 Aerodesigns, Inc. Delivering aerosolizable food products
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung

Also Published As

Publication number Publication date
ES2150022T3 (es) 2000-11-16
DE69518334D1 (de) 2000-09-14
EP0799024B1 (de) 2000-08-09
DK0799024T3 (da) 2001-01-08
GB9426252D0 (en) 1995-02-22
AU4346996A (en) 1996-07-19
PT799024E (pt) 2000-12-29
JPH10511376A (ja) 1998-11-04
GR3034477T3 (en) 2000-12-29
US5955439A (en) 1999-09-21
WO1996019968A1 (en) 1996-07-04
ATE195249T1 (de) 2000-08-15
JP3776124B2 (ja) 2006-05-17
EP0799024A1 (de) 1997-10-08

Similar Documents

Publication Publication Date Title
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
CA2125665A1 (en) Medicaments
GB9425160D0 (en) Medicaments
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
MY108748A (en) Medicaments
MY109758A (en) Aerosol formulations of use for the administration of medicaments by inhalation
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
BR9507746A (pt) Formulação adequada para nebulização processo para preparar a fomulação recipiente uso da formulação e processo para tratar distúrbios respiratórios
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
BR9712125A (pt) Formulação farmaucêutica em aerosol, uso de uma mistura, produto farmacêutico, e, processo de administração de budesonida a um paciente
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee